Pyrethroid ZC Formulations: Polyurea Encapsulation for Stable Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Pyrethroid EC formulations exhibit higher acute oral toxicity and broader biological efficacy compared to SC formulations, while SC formulations have a lower mammalian toxicological profile but restricted biological efficacy, necessitating a formulation that combines the benefits of both.
Innovation Solution
Development of ZC formulations by encapsulating adjuvants within polyurea membranes in pyrethroid SC formulations, which enhances insecticidal efficacy without increasing mammalian toxicity, mimicking EC formulations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If pyrethroid EC formulations are used, then biological efficacy is improved, but mammalian toxicity increases
Solution Approach 1:
The formulation is segmented into two distinct components: pyrethroid active ingredient suspended as fine particles and adjuvant encapsulated in separate polyurea capsules. This segmentation allows each component to function independently - the pyrethroid maintains its low toxicity SC formulation properties while the encapsulated adjuvant provides enhanced insecticidal efficacy when both are present in the formulation
Solution Approach 2:
The polyurea capsule acts as an intermediary carrier that protects the adjuvant from premature interaction with the pyrethroid suspension, preventing crystal growth while enabling controlled release. The capsule wall serves as a mediator that allows the adjuvant to function as an effective insecticide enhancer without causing the instability issues associated with direct mixing
2Productivity
If adjuvants are added to SC formulations to enhance insecticidal efficacy, then biological efficacy is improved, but formulation stability deteriorates due to crystal growth
Solution Approach 1:
The adjuvant is extracted from the continuous aqueous phase and isolated within polyurea capsule shells. This extraction prevents the adjuvant from directly contacting the pyrethroid particles, thereby eliminating the mechanism (Ostwald ripening) that would otherwise cause crystal growth and formulation instability
Solution Approach 2:
The adjuvant is nested within the polyurea capsule structure, creating a hierarchical formulation where the capsule shell provides protective containment. This nested structure allows the adjuvant to be incorporated into the SC formulation without compromising the stability of the pyrethroid suspension, as the adjuvant remains physically separated until release
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
ZC formulations achieve higher insecticidal efficacy against agricultural pests similar to EC formulations while maintaining a lower mammalian toxicity profile, addressing the limitations of both EC and SC formulations.
Implementation Method 1
a suspension concentrate stored in the presence of polymers, or carboxylate esters, or phosphates is unstable towards crystal growth, as a result of Ostwald ripening
Implementation Method 2
the polyurea membrane physically separates the dispersed active ingredient from the adjuvant
Data Source
AI summary
ZC formulations made up of finely milled pyrethroids and encapsulated adjuvants with enhanced insecticidal efficacy of pyrethroid suspension concentrates against insects, without increased mammalian toxicity of the formulation.